HV-101 is an process-optimized, autologous unmodified Tumor-infiltrating lymphocyte (TIL) product fully developed at Hervor. Comparing to conventional TIL product, HV-101 has significant more percentage of stem-progenitor T cells and better functionality.
In the coming phase I/II clinical study, the company will investigate the safety, tolerability, and preliminary Efficacy of HV-101 for patients with recurrent or metastatic solid tumors.
